nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—ABCB1—Mitomycin—urinary bladder cancer	0.0449	0.106	CbGbCtD
Imatinib—SLC22A2—Cisplatin—urinary bladder cancer	0.0353	0.0837	CbGbCtD
Imatinib—ABCG2—Fluorouracil—urinary bladder cancer	0.0306	0.0727	CbGbCtD
Imatinib—ABCG2—Carboplatin—urinary bladder cancer	0.0305	0.0723	CbGbCtD
Imatinib—ABCG2—Cisplatin—urinary bladder cancer	0.026	0.0618	CbGbCtD
Imatinib—ABCG2—Etoposide—urinary bladder cancer	0.0256	0.0607	CbGbCtD
Imatinib—PTGS1—Etoposide—urinary bladder cancer	0.0236	0.056	CbGbCtD
Imatinib—ALB—Fluorouracil—urinary bladder cancer	0.0211	0.0501	CbGbCtD
Imatinib—CYP3A4—Thiotepa—urinary bladder cancer	0.0204	0.0483	CbGbCtD
Imatinib—ABCG2—Doxorubicin—urinary bladder cancer	0.0174	0.0414	CbGbCtD
Imatinib—ABCG2—Methotrexate—urinary bladder cancer	0.0169	0.0401	CbGbCtD
Imatinib—CYP3A5—Etoposide—urinary bladder cancer	0.0142	0.0336	CbGbCtD
Imatinib—ABCB1—Gemcitabine—urinary bladder cancer	0.0129	0.0306	CbGbCtD
Imatinib—CYP1A2—Fluorouracil—urinary bladder cancer	0.0126	0.03	CbGbCtD
Imatinib—ALB—Methotrexate—urinary bladder cancer	0.0116	0.0276	CbGbCtD
Imatinib—CYP2C9—Fluorouracil—urinary bladder cancer	0.0114	0.027	CbGbCtD
Imatinib—CYP1A2—Etoposide—urinary bladder cancer	0.0105	0.025	CbGbCtD
Imatinib—CYP2C9—Cisplatin—urinary bladder cancer	0.00967	0.0229	CbGbCtD
Imatinib—ABCB1—Cisplatin—urinary bladder cancer	0.00939	0.0223	CbGbCtD
Imatinib—ABCB1—Etoposide—urinary bladder cancer	0.00922	0.0219	CbGbCtD
Imatinib—PDGFRA—penis—urinary bladder cancer	0.00638	0.0471	CbGeAlD
Imatinib—ABCB1—Doxorubicin—urinary bladder cancer	0.00629	0.0149	CbGbCtD
Imatinib—ABCB1—Methotrexate—urinary bladder cancer	0.00609	0.0145	CbGbCtD
Imatinib—CYP2D6—Doxorubicin—urinary bladder cancer	0.00593	0.0141	CbGbCtD
Imatinib—CYP3A4—Etoposide—urinary bladder cancer	0.00553	0.0131	CbGbCtD
Imatinib—Ponatinib—FGFR3—urinary bladder cancer	0.00468	0.664	CrCbGaD
Imatinib—CYP3A4—Doxorubicin—urinary bladder cancer	0.00377	0.00894	CbGbCtD
Imatinib—ABCA3—prostate gland—urinary bladder cancer	0.00365	0.027	CbGeAlD
Imatinib—DDR1—prostate gland—urinary bladder cancer	0.00337	0.0249	CbGeAlD
Imatinib—ABCA3—seminal vesicle—urinary bladder cancer	0.00309	0.0228	CbGeAlD
Imatinib—DDR1—seminal vesicle—urinary bladder cancer	0.00285	0.021	CbGeAlD
Imatinib—ABCA3—urethra—urinary bladder cancer	0.00245	0.0181	CbGeAlD
Imatinib—DDR1—smooth muscle tissue—urinary bladder cancer	0.00239	0.0176	CbGeAlD
Imatinib—Ponatinib—SRC—urinary bladder cancer	0.00237	0.336	CrCbGaD
Imatinib—DDR1—urethra—urinary bladder cancer	0.00226	0.0167	CbGeAlD
Imatinib—ABL2—prostate gland—urinary bladder cancer	0.0022	0.0162	CbGeAlD
Imatinib—CYP2C19—urine—urinary bladder cancer	0.0022	0.0162	CbGeAlD
Imatinib—PIP4K2C—prostate gland—urinary bladder cancer	0.00208	0.0154	CbGeAlD
Imatinib—HIPK4—female reproductive system—urinary bladder cancer	0.00202	0.0149	CbGeAlD
Imatinib—CA3—prostate gland—urinary bladder cancer	0.00199	0.0147	CbGeAlD
Imatinib—LCK—prostate gland—urinary bladder cancer	0.00185	0.0136	CbGeAlD
Imatinib—CA14—prostate gland—urinary bladder cancer	0.0018	0.0133	CbGeAlD
Imatinib—ABCA3—vagina—urinary bladder cancer	0.0018	0.0133	CbGeAlD
Imatinib—CYP1A2—urine—urinary bladder cancer	0.00179	0.0132	CbGeAlD
Imatinib—PIP4K2C—seminal vesicle—urinary bladder cancer	0.00176	0.013	CbGeAlD
Imatinib—CYP2C9—urine—urinary bladder cancer	0.0017	0.0126	CbGeAlD
Imatinib—DDR1—vagina—urinary bladder cancer	0.00166	0.0123	CbGeAlD
Imatinib—NQO2—prostate gland—urinary bladder cancer	0.00153	0.0113	CbGeAlD
Imatinib—CA14—seminal vesicle—urinary bladder cancer	0.00153	0.0113	CbGeAlD
Imatinib—PDGFRA—prostate gland—urinary bladder cancer	0.00153	0.0113	CbGeAlD
Imatinib—CA7—renal system—urinary bladder cancer	0.00148	0.0109	CbGeAlD
Imatinib—PIP4K2C—urethra—urinary bladder cancer	0.00139	0.0103	CbGeAlD
Imatinib—CSF1R—prostate gland—urinary bladder cancer	0.00134	0.0099	CbGeAlD
Imatinib—CYP3A4—urine—urinary bladder cancer	0.0013	0.00958	CbGeAlD
Imatinib—NQO2—seminal vesicle—urinary bladder cancer	0.00129	0.00954	CbGeAlD
Imatinib—CYP2D6—urine—urinary bladder cancer	0.00128	0.00943	CbGeAlD
Imatinib—LCK—urethra—urinary bladder cancer	0.00124	0.00913	CbGeAlD
Imatinib—SLC47A1—prostate gland—urinary bladder cancer	0.00123	0.00905	CbGeAlD
Imatinib—KIT—prostate gland—urinary bladder cancer	0.00122	0.00899	CbGeAlD
Imatinib—PDGFRB—prostate gland—urinary bladder cancer	0.00119	0.00878	CbGeAlD
Imatinib—ABCA3—lymph node—urinary bladder cancer	0.00117	0.00861	CbGeAlD
Imatinib—PIP4K2C—female reproductive system—urinary bladder cancer	0.00114	0.00838	CbGeAlD
Imatinib—CSF1R—seminal vesicle—urinary bladder cancer	0.00114	0.00838	CbGeAlD
Imatinib—ORM1—prostate gland—urinary bladder cancer	0.00112	0.00824	CbGeAlD
Imatinib—ABL2—vagina—urinary bladder cancer	0.00109	0.00801	CbGeAlD
Imatinib—PDGFRA—smooth muscle tissue—urinary bladder cancer	0.00108	0.00797	CbGeAlD
Imatinib—DDR1—lymph node—urinary bladder cancer	0.00108	0.00794	CbGeAlD
Imatinib—ABL1—prostate gland—urinary bladder cancer	0.00106	0.00783	CbGeAlD
Imatinib—NQO2—renal system—urinary bladder cancer	0.00104	0.00769	CbGeAlD
Imatinib—PDGFRA—renal system—urinary bladder cancer	0.00104	0.00767	CbGeAlD
Imatinib—CA9—female reproductive system—urinary bladder cancer	0.00104	0.00766	CbGeAlD
Imatinib—SLC47A1—seminal vesicle—urinary bladder cancer	0.00104	0.00765	CbGeAlD
Imatinib—KIT—seminal vesicle—urinary bladder cancer	0.00103	0.00761	CbGeAlD
Imatinib—PIP4K2C—vagina—urinary bladder cancer	0.00103	0.00758	CbGeAlD
Imatinib—NQO2—urethra—urinary bladder cancer	0.00102	0.00755	CbGeAlD
Imatinib—PDGFRB—seminal vesicle—urinary bladder cancer	0.00101	0.00743	CbGeAlD
Imatinib—SLC22A2—renal system—urinary bladder cancer	0.000987	0.00728	CbGeAlD
Imatinib—CA3—vagina—urinary bladder cancer	0.000981	0.00724	CbGeAlD
Imatinib—CA12—renal system—urinary bladder cancer	0.000959	0.00708	CbGeAlD
Imatinib—CSF1R—smooth muscle tissue—urinary bladder cancer	0.000951	0.00701	CbGeAlD
Imatinib—ABL1—Epirubicin—Valrubicin—urinary bladder cancer	0.000916	0.166	CbGdCrCtD
Imatinib—ABL1—Idarubicin—Valrubicin—urinary bladder cancer	0.000916	0.166	CbGdCrCtD
Imatinib—ABL1—Doxorubicin—Valrubicin—urinary bladder cancer	0.000916	0.166	CbGdCrCtD
Imatinib—ABL1—Daunorubicin—Valrubicin—urinary bladder cancer	0.000916	0.166	CbGdCrCtD
Imatinib—LCK—vagina—urinary bladder cancer	0.000912	0.00673	CbGeAlD
Imatinib—CSF1R—urethra—urinary bladder cancer	0.000899	0.00663	CbGeAlD
Imatinib—ABL1—seminal vesicle—urinary bladder cancer	0.000898	0.00662	CbGeAlD
Imatinib—KIT—epithelium—urinary bladder cancer	0.000896	0.00661	CbGeAlD
Imatinib—PDGFRB—epithelium—urinary bladder cancer	0.000875	0.00645	CbGeAlD
Imatinib—KIT—smooth muscle tissue—urinary bladder cancer	0.000863	0.00637	CbGeAlD
Imatinib—PDGFRB—smooth muscle tissue—urinary bladder cancer	0.000843	0.00622	CbGeAlD
Imatinib—SLC47A1—renal system—urinary bladder cancer	0.000836	0.00617	CbGeAlD
Imatinib—NQO2—female reproductive system—urinary bladder cancer	0.000835	0.00616	CbGeAlD
Imatinib—PDGFRA—female reproductive system—urinary bladder cancer	0.000832	0.00614	CbGeAlD
Imatinib—KIT—renal system—urinary bladder cancer	0.000831	0.00613	CbGeAlD
Imatinib—SLC47A1—urethra—urinary bladder cancer	0.000821	0.00606	CbGeAlD
Imatinib—KIT—urethra—urinary bladder cancer	0.000816	0.00602	CbGeAlD
Imatinib—PDGFRB—renal system—urinary bladder cancer	0.000812	0.00599	CbGeAlD
Imatinib—PDGFRB—urethra—urinary bladder cancer	0.000797	0.00588	CbGeAlD
Imatinib—CA12—female reproductive system—urinary bladder cancer	0.000768	0.00567	CbGeAlD
Imatinib—CA1—renal system—urinary bladder cancer	0.00076	0.00561	CbGeAlD
Imatinib—NQO2—vagina—urinary bladder cancer	0.000755	0.00557	CbGeAlD
Imatinib—PDGFRA—vagina—urinary bladder cancer	0.000753	0.00555	CbGeAlD
Imatinib—ABL1—smooth muscle tissue—urinary bladder cancer	0.000751	0.00554	CbGeAlD
Imatinib—CSF1R—female reproductive system—urinary bladder cancer	0.000733	0.00541	CbGeAlD
Imatinib—ABL1—renal system—urinary bladder cancer	0.000723	0.00534	CbGeAlD
Imatinib—CA2—prostate gland—urinary bladder cancer	0.000723	0.00533	CbGeAlD
Imatinib—ABL1—urethra—urinary bladder cancer	0.000711	0.00524	CbGeAlD
Imatinib—ABL2—lymph node—urinary bladder cancer	0.000703	0.00518	CbGeAlD
Imatinib—SLC22A1—renal system—urinary bladder cancer	0.000697	0.00514	CbGeAlD
Imatinib—SLC47A1—female reproductive system—urinary bladder cancer	0.000669	0.00494	CbGeAlD
Imatinib—ABCG2—prostate gland—urinary bladder cancer	0.000669	0.00494	CbGeAlD
Imatinib—KIT—female reproductive system—urinary bladder cancer	0.000666	0.00491	CbGeAlD
Imatinib—PIP4K2C—lymph node—urinary bladder cancer	0.000665	0.0049	CbGeAlD
Imatinib—CSF1R—vagina—urinary bladder cancer	0.000663	0.00489	CbGeAlD
Imatinib—PDGFRB—female reproductive system—urinary bladder cancer	0.00065	0.0048	CbGeAlD
Imatinib—CA3—lymph node—urinary bladder cancer	0.000635	0.00468	CbGeAlD
Imatinib—CYP3A5—prostate gland—urinary bladder cancer	0.000621	0.00458	CbGeAlD
Imatinib—CA2—seminal vesicle—urinary bladder cancer	0.000611	0.00451	CbGeAlD
Imatinib—ORM1—female reproductive system—urinary bladder cancer	0.00061	0.0045	CbGeAlD
Imatinib—CA1—female reproductive system—urinary bladder cancer	0.000609	0.00449	CbGeAlD
Imatinib—SLC47A1—vagina—urinary bladder cancer	0.000605	0.00447	CbGeAlD
Imatinib—KIT—vagina—urinary bladder cancer	0.000602	0.00444	CbGeAlD
Imatinib—LCK—lymph node—urinary bladder cancer	0.00059	0.00435	CbGeAlD
Imatinib—PDGFRB—vagina—urinary bladder cancer	0.000588	0.00434	CbGeAlD
Imatinib—ABL1—female reproductive system—urinary bladder cancer	0.000579	0.00427	CbGeAlD
Imatinib—ABCG2—seminal vesicle—urinary bladder cancer	0.000566	0.00418	CbGeAlD
Imatinib—PTGS1—prostate gland—urinary bladder cancer	0.000558	0.00412	CbGeAlD
Imatinib—CA2—epithelium—urinary bladder cancer	0.000531	0.00392	CbGeAlD
Imatinib—ABL1—vagina—urinary bladder cancer	0.000524	0.00387	CbGeAlD
Imatinib—CA2—smooth muscle tissue—urinary bladder cancer	0.000512	0.00377	CbGeAlD
Imatinib—SLC22A1—vagina—urinary bladder cancer	0.000505	0.00373	CbGeAlD
Imatinib—CA2—renal system—urinary bladder cancer	0.000493	0.00363	CbGeAlD
Imatinib—NQO2—lymph node—urinary bladder cancer	0.000488	0.0036	CbGeAlD
Imatinib—PDGFRA—lymph node—urinary bladder cancer	0.000487	0.00359	CbGeAlD
Imatinib—PTGS1—seminal vesicle—urinary bladder cancer	0.000472	0.00348	CbGeAlD
Imatinib—ABCG2—urethra—urinary bladder cancer	0.000448	0.00331	CbGeAlD
Imatinib—CYP1A2—renal system—urinary bladder cancer	0.000439	0.00324	CbGeAlD
Imatinib—CSF1R—lymph node—urinary bladder cancer	0.000429	0.00316	CbGeAlD
Imatinib—CYP3A5—renal system—urinary bladder cancer	0.000423	0.00312	CbGeAlD
Imatinib—PTGS1—epithelium—urinary bladder cancer	0.00041	0.00303	CbGeAlD
Imatinib—PTGS1—smooth muscle tissue—urinary bladder cancer	0.000395	0.00292	CbGeAlD
Imatinib—CA2—female reproductive system—urinary bladder cancer	0.000394	0.00291	CbGeAlD
Imatinib—SLC47A1—lymph node—urinary bladder cancer	0.000392	0.00289	CbGeAlD
Imatinib—CYP2C19—vagina—urinary bladder cancer	0.000389	0.00287	CbGeAlD
Imatinib—KIT—lymph node—urinary bladder cancer	0.000389	0.00287	CbGeAlD
Imatinib—PTGS1—renal system—urinary bladder cancer	0.00038	0.00281	CbGeAlD
Imatinib—PDGFRB—lymph node—urinary bladder cancer	0.00038	0.00281	CbGeAlD
Imatinib—CA2—vagina—urinary bladder cancer	0.000357	0.00263	CbGeAlD
Imatinib—ORM1—lymph node—urinary bladder cancer	0.000357	0.00263	CbGeAlD
Imatinib—CA1—lymph node—urinary bladder cancer	0.000356	0.00263	CbGeAlD
Imatinib—ABL1—lymph node—urinary bladder cancer	0.000339	0.0025	CbGeAlD
Imatinib—CYP2C9—female reproductive system—urinary bladder cancer	0.000334	0.00246	CbGeAlD
Imatinib—ABCG2—vagina—urinary bladder cancer	0.00033	0.00244	CbGeAlD
Imatinib—ABCB1—prostate gland—urinary bladder cancer	0.00033	0.00243	CbGeAlD
Imatinib—ABL1—Daunorubicin—Epirubicin—urinary bladder cancer	0.000319	0.0579	CbGdCrCtD
Imatinib—ABL1—Idarubicin—Epirubicin—urinary bladder cancer	0.000319	0.0579	CbGdCrCtD
Imatinib—ABL1—Doxorubicin—Epirubicin—urinary bladder cancer	0.000319	0.0579	CbGdCrCtD
Imatinib—CYP3A4—renal system—urinary bladder cancer	0.000318	0.00234	CbGeAlD
Imatinib—ALB—lymph node—urinary bladder cancer	0.000313	0.00231	CbGeAlD
Imatinib—CYP2D6—renal system—urinary bladder cancer	0.000313	0.00231	CbGeAlD
Imatinib—CYP3A5—vagina—urinary bladder cancer	0.000307	0.00226	CbGeAlD
Imatinib—PTGS1—female reproductive system—urinary bladder cancer	0.000305	0.00225	CbGeAlD
Imatinib—ABL1—Epirubicin—Doxorubicin—urinary bladder cancer	0.000295	0.0536	CbGdCrCtD
Imatinib—ABL1—Idarubicin—Doxorubicin—urinary bladder cancer	0.000295	0.0536	CbGdCrCtD
Imatinib—ABL1—Daunorubicin—Doxorubicin—urinary bladder cancer	0.000295	0.0536	CbGdCrCtD
Imatinib—ABCB1—seminal vesicle—urinary bladder cancer	0.000279	0.00206	CbGeAlD
Imatinib—PTGS1—vagina—urinary bladder cancer	0.000276	0.00203	CbGeAlD
Imatinib—CYP3A4—female reproductive system—urinary bladder cancer	0.000255	0.00188	CbGeAlD
Imatinib—CYP2D6—female reproductive system—urinary bladder cancer	0.00025	0.00185	CbGeAlD
Imatinib—ABCB1—epithelium—urinary bladder cancer	0.000243	0.00179	CbGeAlD
Imatinib—CA2—lymph node—urinary bladder cancer	0.000231	0.0017	CbGeAlD
Imatinib—ABCB1—renal system—urinary bladder cancer	0.000225	0.00166	CbGeAlD
Imatinib—ABCB1—urethra—urinary bladder cancer	0.000221	0.00163	CbGeAlD
Imatinib—ABCG2—lymph node—urinary bladder cancer	0.000214	0.00158	CbGeAlD
Imatinib—ABCB1—female reproductive system—urinary bladder cancer	0.00018	0.00133	CbGeAlD
Imatinib—PTGS1—lymph node—urinary bladder cancer	0.000178	0.00131	CbGeAlD
Imatinib—ABCB1—vagina—urinary bladder cancer	0.000163	0.0012	CbGeAlD
Imatinib—ABCB1—lymph node—urinary bladder cancer	0.000105	0.000777	CbGeAlD
Imatinib—Haematuria—Doxorubicin—urinary bladder cancer	8.77e-05	0.000348	CcSEcCtD
Imatinib—Connective tissue disorder—Epirubicin—urinary bladder cancer	8.77e-05	0.000348	CcSEcCtD
Imatinib—Urethral disorder—Epirubicin—urinary bladder cancer	8.75e-05	0.000347	CcSEcCtD
Imatinib—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	8.7e-05	0.000345	CcSEcCtD
Imatinib—Epistaxis—Doxorubicin—urinary bladder cancer	8.68e-05	0.000344	CcSEcCtD
Imatinib—Angiopathy—Methotrexate—urinary bladder cancer	8.65e-05	0.000343	CcSEcCtD
Imatinib—Sinusitis—Doxorubicin—urinary bladder cancer	8.63e-05	0.000342	CcSEcCtD
Imatinib—Immune system disorder—Methotrexate—urinary bladder cancer	8.61e-05	0.000342	CcSEcCtD
Imatinib—Dizziness—Fluorouracil—urinary bladder cancer	8.61e-05	0.000342	CcSEcCtD
Imatinib—Mediastinal disorder—Methotrexate—urinary bladder cancer	8.59e-05	0.000341	CcSEcCtD
Imatinib—Agranulocytosis—Doxorubicin—urinary bladder cancer	8.58e-05	0.000341	CcSEcCtD
Imatinib—Chills—Methotrexate—urinary bladder cancer	8.56e-05	0.000339	CcSEcCtD
Imatinib—Diarrhoea—Cisplatin—urinary bladder cancer	8.45e-05	0.000335	CcSEcCtD
Imatinib—Erythema multiforme—Epirubicin—urinary bladder cancer	8.44e-05	0.000335	CcSEcCtD
Imatinib—Alopecia—Methotrexate—urinary bladder cancer	8.43e-05	0.000334	CcSEcCtD
Imatinib—Vomiting—Gemcitabine—urinary bladder cancer	8.42e-05	0.000334	CcSEcCtD
Imatinib—Mental disorder—Methotrexate—urinary bladder cancer	8.35e-05	0.000331	CcSEcCtD
Imatinib—Rash—Gemcitabine—urinary bladder cancer	8.35e-05	0.000331	CcSEcCtD
Imatinib—Dermatitis—Gemcitabine—urinary bladder cancer	8.34e-05	0.000331	CcSEcCtD
Imatinib—Eye disorder—Epirubicin—urinary bladder cancer	8.34e-05	0.000331	CcSEcCtD
Imatinib—Hypersensitivity—Etoposide—urinary bladder cancer	8.33e-05	0.000331	CcSEcCtD
Imatinib—Tinnitus—Epirubicin—urinary bladder cancer	8.32e-05	0.00033	CcSEcCtD
Imatinib—Erythema—Methotrexate—urinary bladder cancer	8.3e-05	0.000329	CcSEcCtD
Imatinib—Malnutrition—Methotrexate—urinary bladder cancer	8.3e-05	0.000329	CcSEcCtD
Imatinib—Haemoglobin—Doxorubicin—urinary bladder cancer	8.3e-05	0.000329	CcSEcCtD
Imatinib—Headache—Gemcitabine—urinary bladder cancer	8.3e-05	0.000329	CcSEcCtD
Imatinib—Cardiac disorder—Epirubicin—urinary bladder cancer	8.28e-05	0.000329	CcSEcCtD
Imatinib—Flushing—Epirubicin—urinary bladder cancer	8.28e-05	0.000329	CcSEcCtD
Imatinib—Vomiting—Fluorouracil—urinary bladder cancer	8.28e-05	0.000329	CcSEcCtD
Imatinib—Rhinitis—Doxorubicin—urinary bladder cancer	8.28e-05	0.000328	CcSEcCtD
Imatinib—Haemorrhage—Doxorubicin—urinary bladder cancer	8.26e-05	0.000328	CcSEcCtD
Imatinib—Hepatitis—Doxorubicin—urinary bladder cancer	8.26e-05	0.000328	CcSEcCtD
Imatinib—Hypoaesthesia—Doxorubicin—urinary bladder cancer	8.22e-05	0.000326	CcSEcCtD
Imatinib—Rash—Fluorouracil—urinary bladder cancer	8.21e-05	0.000326	CcSEcCtD
Imatinib—Dermatitis—Fluorouracil—urinary bladder cancer	8.2e-05	0.000325	CcSEcCtD
Imatinib—Pharyngitis—Doxorubicin—urinary bladder cancer	8.2e-05	0.000325	CcSEcCtD
Imatinib—Headache—Fluorouracil—urinary bladder cancer	8.16e-05	0.000324	CcSEcCtD
Imatinib—Urinary tract disorder—Doxorubicin—urinary bladder cancer	8.15e-05	0.000324	CcSEcCtD
Imatinib—Oedema peripheral—Doxorubicin—urinary bladder cancer	8.13e-05	0.000323	CcSEcCtD
Imatinib—Dysgeusia—Methotrexate—urinary bladder cancer	8.13e-05	0.000323	CcSEcCtD
Imatinib—Asthenia—Etoposide—urinary bladder cancer	8.12e-05	0.000322	CcSEcCtD
Imatinib—Connective tissue disorder—Doxorubicin—urinary bladder cancer	8.11e-05	0.000322	CcSEcCtD
Imatinib—Angiopathy—Epirubicin—urinary bladder cancer	8.1e-05	0.000321	CcSEcCtD
Imatinib—Urethral disorder—Doxorubicin—urinary bladder cancer	8.09e-05	0.000321	CcSEcCtD
Imatinib—Immune system disorder—Epirubicin—urinary bladder cancer	8.06e-05	0.00032	CcSEcCtD
Imatinib—Mediastinal disorder—Epirubicin—urinary bladder cancer	8.04e-05	0.000319	CcSEcCtD
Imatinib—Back pain—Methotrexate—urinary bladder cancer	8.03e-05	0.000319	CcSEcCtD
Imatinib—Chills—Epirubicin—urinary bladder cancer	8.01e-05	0.000318	CcSEcCtD
Imatinib—Pruritus—Etoposide—urinary bladder cancer	8e-05	0.000317	CcSEcCtD
Imatinib—Arrhythmia—Epirubicin—urinary bladder cancer	7.97e-05	0.000316	CcSEcCtD
Imatinib—Alopecia—Epirubicin—urinary bladder cancer	7.89e-05	0.000313	CcSEcCtD
Imatinib—Nausea—Gemcitabine—urinary bladder cancer	7.87e-05	0.000312	CcSEcCtD
Imatinib—Vomiting—Cisplatin—urinary bladder cancer	7.85e-05	0.000311	CcSEcCtD
Imatinib—Vision blurred—Methotrexate—urinary bladder cancer	7.82e-05	0.00031	CcSEcCtD
Imatinib—Mental disorder—Epirubicin—urinary bladder cancer	7.82e-05	0.00031	CcSEcCtD
Imatinib—Erythema multiforme—Doxorubicin—urinary bladder cancer	7.81e-05	0.00031	CcSEcCtD
Imatinib—Rash—Cisplatin—urinary bladder cancer	7.78e-05	0.000309	CcSEcCtD
Imatinib—Dermatitis—Cisplatin—urinary bladder cancer	7.78e-05	0.000309	CcSEcCtD
Imatinib—Malnutrition—Epirubicin—urinary bladder cancer	7.77e-05	0.000308	CcSEcCtD
Imatinib—Erythema—Epirubicin—urinary bladder cancer	7.77e-05	0.000308	CcSEcCtD
Imatinib—Diarrhoea—Etoposide—urinary bladder cancer	7.74e-05	0.000307	CcSEcCtD
Imatinib—Nausea—Fluorouracil—urinary bladder cancer	7.74e-05	0.000307	CcSEcCtD
Imatinib—Eye disorder—Doxorubicin—urinary bladder cancer	7.72e-05	0.000306	CcSEcCtD
Imatinib—Ill-defined disorder—Methotrexate—urinary bladder cancer	7.7e-05	0.000306	CcSEcCtD
Imatinib—Tinnitus—Doxorubicin—urinary bladder cancer	7.7e-05	0.000305	CcSEcCtD
Imatinib—Anaemia—Methotrexate—urinary bladder cancer	7.67e-05	0.000304	CcSEcCtD
Imatinib—Flushing—Doxorubicin—urinary bladder cancer	7.66e-05	0.000304	CcSEcCtD
Imatinib—Cardiac disorder—Doxorubicin—urinary bladder cancer	7.66e-05	0.000304	CcSEcCtD
Imatinib—Flatulence—Epirubicin—urinary bladder cancer	7.66e-05	0.000304	CcSEcCtD
Imatinib—Dysgeusia—Epirubicin—urinary bladder cancer	7.61e-05	0.000302	CcSEcCtD
Imatinib—Back pain—Epirubicin—urinary bladder cancer	7.51e-05	0.000298	CcSEcCtD
Imatinib—Angiopathy—Doxorubicin—urinary bladder cancer	7.49e-05	0.000297	CcSEcCtD
Imatinib—Malaise—Methotrexate—urinary bladder cancer	7.49e-05	0.000297	CcSEcCtD
Imatinib—Dizziness—Etoposide—urinary bladder cancer	7.48e-05	0.000297	CcSEcCtD
Imatinib—Muscle spasms—Epirubicin—urinary bladder cancer	7.47e-05	0.000296	CcSEcCtD
Imatinib—Immune system disorder—Doxorubicin—urinary bladder cancer	7.46e-05	0.000296	CcSEcCtD
Imatinib—Vertigo—Methotrexate—urinary bladder cancer	7.46e-05	0.000296	CcSEcCtD
Imatinib—Mediastinal disorder—Doxorubicin—urinary bladder cancer	7.44e-05	0.000295	CcSEcCtD
Imatinib—Leukopenia—Methotrexate—urinary bladder cancer	7.43e-05	0.000295	CcSEcCtD
Imatinib—Chills—Doxorubicin—urinary bladder cancer	7.41e-05	0.000294	CcSEcCtD
Imatinib—Arrhythmia—Doxorubicin—urinary bladder cancer	7.38e-05	0.000293	CcSEcCtD
Imatinib—Nausea—Cisplatin—urinary bladder cancer	7.33e-05	0.000291	CcSEcCtD
Imatinib—Vision blurred—Epirubicin—urinary bladder cancer	7.32e-05	0.00029	CcSEcCtD
Imatinib—Alopecia—Doxorubicin—urinary bladder cancer	7.3e-05	0.000289	CcSEcCtD
Imatinib—Cough—Methotrexate—urinary bladder cancer	7.24e-05	0.000287	CcSEcCtD
Imatinib—Mental disorder—Doxorubicin—urinary bladder cancer	7.23e-05	0.000287	CcSEcCtD
Imatinib—Ill-defined disorder—Epirubicin—urinary bladder cancer	7.21e-05	0.000286	CcSEcCtD
Imatinib—Convulsion—Methotrexate—urinary bladder cancer	7.19e-05	0.000285	CcSEcCtD
Imatinib—Vomiting—Etoposide—urinary bladder cancer	7.19e-05	0.000285	CcSEcCtD
Imatinib—Malnutrition—Doxorubicin—urinary bladder cancer	7.19e-05	0.000285	CcSEcCtD
Imatinib—Erythema—Doxorubicin—urinary bladder cancer	7.19e-05	0.000285	CcSEcCtD
Imatinib—Anaemia—Epirubicin—urinary bladder cancer	7.18e-05	0.000285	CcSEcCtD
Imatinib—Rash—Etoposide—urinary bladder cancer	7.13e-05	0.000283	CcSEcCtD
Imatinib—Dermatitis—Etoposide—urinary bladder cancer	7.13e-05	0.000283	CcSEcCtD
Imatinib—Headache—Etoposide—urinary bladder cancer	7.09e-05	0.000281	CcSEcCtD
Imatinib—Flatulence—Doxorubicin—urinary bladder cancer	7.08e-05	0.000281	CcSEcCtD
Imatinib—Chest pain—Methotrexate—urinary bladder cancer	7.07e-05	0.00028	CcSEcCtD
Imatinib—Arthralgia—Methotrexate—urinary bladder cancer	7.07e-05	0.00028	CcSEcCtD
Imatinib—Myalgia—Methotrexate—urinary bladder cancer	7.07e-05	0.00028	CcSEcCtD
Imatinib—Dysgeusia—Doxorubicin—urinary bladder cancer	7.04e-05	0.000279	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	7.02e-05	0.000278	CcSEcCtD
Imatinib—Malaise—Epirubicin—urinary bladder cancer	7.01e-05	0.000278	CcSEcCtD
Imatinib—Discomfort—Methotrexate—urinary bladder cancer	6.98e-05	0.000277	CcSEcCtD
Imatinib—Vertigo—Epirubicin—urinary bladder cancer	6.98e-05	0.000277	CcSEcCtD
Imatinib—Syncope—Epirubicin—urinary bladder cancer	6.97e-05	0.000276	CcSEcCtD
Imatinib—Leukopenia—Epirubicin—urinary bladder cancer	6.95e-05	0.000276	CcSEcCtD
Imatinib—Back pain—Doxorubicin—urinary bladder cancer	6.95e-05	0.000276	CcSEcCtD
Imatinib—Muscle spasms—Doxorubicin—urinary bladder cancer	6.91e-05	0.000274	CcSEcCtD
Imatinib—Palpitations—Epirubicin—urinary bladder cancer	6.87e-05	0.000272	CcSEcCtD
Imatinib—Confusional state—Methotrexate—urinary bladder cancer	6.83e-05	0.000271	CcSEcCtD
Imatinib—Loss of consciousness—Epirubicin—urinary bladder cancer	6.83e-05	0.000271	CcSEcCtD
Imatinib—Cough—Epirubicin—urinary bladder cancer	6.78e-05	0.000269	CcSEcCtD
Imatinib—Anaphylactic shock—Methotrexate—urinary bladder cancer	6.78e-05	0.000269	CcSEcCtD
Imatinib—Vision blurred—Doxorubicin—urinary bladder cancer	6.77e-05	0.000269	CcSEcCtD
Imatinib—Convulsion—Epirubicin—urinary bladder cancer	6.73e-05	0.000267	CcSEcCtD
Imatinib—Infection—Methotrexate—urinary bladder cancer	6.73e-05	0.000267	CcSEcCtD
Imatinib—Nausea—Etoposide—urinary bladder cancer	6.72e-05	0.000267	CcSEcCtD
Imatinib—Hypertension—Epirubicin—urinary bladder cancer	6.71e-05	0.000266	CcSEcCtD
Imatinib—Ill-defined disorder—Doxorubicin—urinary bladder cancer	6.67e-05	0.000265	CcSEcCtD
Imatinib—Nervous system disorder—Methotrexate—urinary bladder cancer	6.64e-05	0.000264	CcSEcCtD
Imatinib—Anaemia—Doxorubicin—urinary bladder cancer	6.64e-05	0.000264	CcSEcCtD
Imatinib—Thrombocytopenia—Methotrexate—urinary bladder cancer	6.63e-05	0.000263	CcSEcCtD
Imatinib—Arthralgia—Epirubicin—urinary bladder cancer	6.61e-05	0.000262	CcSEcCtD
Imatinib—Myalgia—Epirubicin—urinary bladder cancer	6.61e-05	0.000262	CcSEcCtD
Imatinib—Chest pain—Epirubicin—urinary bladder cancer	6.61e-05	0.000262	CcSEcCtD
Imatinib—Anxiety—Epirubicin—urinary bladder cancer	6.59e-05	0.000261	CcSEcCtD
Imatinib—Skin disorder—Methotrexate—urinary bladder cancer	6.58e-05	0.000261	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	6.57e-05	0.000261	CcSEcCtD
Imatinib—Hyperhidrosis—Methotrexate—urinary bladder cancer	6.55e-05	0.00026	CcSEcCtD
Imatinib—Discomfort—Epirubicin—urinary bladder cancer	6.53e-05	0.000259	CcSEcCtD
Imatinib—Malaise—Doxorubicin—urinary bladder cancer	6.48e-05	0.000257	CcSEcCtD
Imatinib—Dry mouth—Epirubicin—urinary bladder cancer	6.47e-05	0.000257	CcSEcCtD
Imatinib—Vertigo—Doxorubicin—urinary bladder cancer	6.46e-05	0.000256	CcSEcCtD
Imatinib—Anorexia—Methotrexate—urinary bladder cancer	6.46e-05	0.000256	CcSEcCtD
Imatinib—Syncope—Doxorubicin—urinary bladder cancer	6.45e-05	0.000256	CcSEcCtD
Imatinib—Leukopenia—Doxorubicin—urinary bladder cancer	6.43e-05	0.000255	CcSEcCtD
Imatinib—Confusional state—Epirubicin—urinary bladder cancer	6.39e-05	0.000254	CcSEcCtD
Imatinib—Palpitations—Doxorubicin—urinary bladder cancer	6.35e-05	0.000252	CcSEcCtD
Imatinib—Oedema—Epirubicin—urinary bladder cancer	6.34e-05	0.000252	CcSEcCtD
Imatinib—Anaphylactic shock—Epirubicin—urinary bladder cancer	6.34e-05	0.000252	CcSEcCtD
Imatinib—Hypotension—Methotrexate—urinary bladder cancer	6.33e-05	0.000251	CcSEcCtD
Imatinib—Loss of consciousness—Doxorubicin—urinary bladder cancer	6.32e-05	0.000251	CcSEcCtD
Imatinib—Infection—Epirubicin—urinary bladder cancer	6.3e-05	0.00025	CcSEcCtD
Imatinib—Cough—Doxorubicin—urinary bladder cancer	6.27e-05	0.000249	CcSEcCtD
Imatinib—Shock—Epirubicin—urinary bladder cancer	6.24e-05	0.000247	CcSEcCtD
Imatinib—Convulsion—Doxorubicin—urinary bladder cancer	6.23e-05	0.000247	CcSEcCtD
Imatinib—Nervous system disorder—Epirubicin—urinary bladder cancer	6.22e-05	0.000247	CcSEcCtD
Imatinib—Thrombocytopenia—Epirubicin—urinary bladder cancer	6.21e-05	0.000246	CcSEcCtD
Imatinib—Hypertension—Doxorubicin—urinary bladder cancer	6.21e-05	0.000246	CcSEcCtD
Imatinib—Tachycardia—Epirubicin—urinary bladder cancer	6.19e-05	0.000245	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	6.17e-05	0.000245	CcSEcCtD
Imatinib—Skin disorder—Epirubicin—urinary bladder cancer	6.16e-05	0.000244	CcSEcCtD
Imatinib—Hyperhidrosis—Epirubicin—urinary bladder cancer	6.13e-05	0.000243	CcSEcCtD
Imatinib—Insomnia—Methotrexate—urinary bladder cancer	6.13e-05	0.000243	CcSEcCtD
Imatinib—Arthralgia—Doxorubicin—urinary bladder cancer	6.12e-05	0.000243	CcSEcCtD
Imatinib—Chest pain—Doxorubicin—urinary bladder cancer	6.12e-05	0.000243	CcSEcCtD
Imatinib—Myalgia—Doxorubicin—urinary bladder cancer	6.12e-05	0.000243	CcSEcCtD
Imatinib—Anxiety—Doxorubicin—urinary bladder cancer	6.1e-05	0.000242	CcSEcCtD
Imatinib—Paraesthesia—Methotrexate—urinary bladder cancer	6.08e-05	0.000241	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	6.08e-05	0.000241	CcSEcCtD
Imatinib—Discomfort—Doxorubicin—urinary bladder cancer	6.05e-05	0.00024	CcSEcCtD
Imatinib—Anorexia—Epirubicin—urinary bladder cancer	6.04e-05	0.00024	CcSEcCtD
Imatinib—Dyspnoea—Methotrexate—urinary bladder cancer	6.04e-05	0.00024	CcSEcCtD
Imatinib—Somnolence—Methotrexate—urinary bladder cancer	6.02e-05	0.000239	CcSEcCtD
Imatinib—Dry mouth—Doxorubicin—urinary bladder cancer	5.99e-05	0.000237	CcSEcCtD
Imatinib—Dyspepsia—Methotrexate—urinary bladder cancer	5.96e-05	0.000237	CcSEcCtD
Imatinib—Hypotension—Epirubicin—urinary bladder cancer	5.92e-05	0.000235	CcSEcCtD
Imatinib—Confusional state—Doxorubicin—urinary bladder cancer	5.92e-05	0.000235	CcSEcCtD
Imatinib—Decreased appetite—Methotrexate—urinary bladder cancer	5.89e-05	0.000234	CcSEcCtD
Imatinib—Anaphylactic shock—Doxorubicin—urinary bladder cancer	5.87e-05	0.000233	CcSEcCtD
Imatinib—Oedema—Doxorubicin—urinary bladder cancer	5.87e-05	0.000233	CcSEcCtD
Imatinib—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	5.85e-05	0.000232	CcSEcCtD
Imatinib—Fatigue—Methotrexate—urinary bladder cancer	5.84e-05	0.000232	CcSEcCtD
Imatinib—Infection—Doxorubicin—urinary bladder cancer	5.83e-05	0.000231	CcSEcCtD
Imatinib—Pain—Methotrexate—urinary bladder cancer	5.79e-05	0.00023	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	5.78e-05	0.000229	CcSEcCtD
Imatinib—Shock—Doxorubicin—urinary bladder cancer	5.77e-05	0.000229	CcSEcCtD
Imatinib—Nervous system disorder—Doxorubicin—urinary bladder cancer	5.75e-05	0.000228	CcSEcCtD
Imatinib—Thrombocytopenia—Doxorubicin—urinary bladder cancer	5.74e-05	0.000228	CcSEcCtD
Imatinib—Insomnia—Epirubicin—urinary bladder cancer	5.73e-05	0.000227	CcSEcCtD
Imatinib—Tachycardia—Doxorubicin—urinary bladder cancer	5.73e-05	0.000227	CcSEcCtD
Imatinib—Skin disorder—Doxorubicin—urinary bladder cancer	5.7e-05	0.000226	CcSEcCtD
Imatinib—Paraesthesia—Epirubicin—urinary bladder cancer	5.69e-05	0.000226	CcSEcCtD
Imatinib—Hyperhidrosis—Doxorubicin—urinary bladder cancer	5.67e-05	0.000225	CcSEcCtD
Imatinib—Dyspnoea—Epirubicin—urinary bladder cancer	5.65e-05	0.000224	CcSEcCtD
Imatinib—Somnolence—Epirubicin—urinary bladder cancer	5.64e-05	0.000224	CcSEcCtD
Imatinib—Anorexia—Doxorubicin—urinary bladder cancer	5.59e-05	0.000222	CcSEcCtD
Imatinib—Feeling abnormal—Methotrexate—urinary bladder cancer	5.58e-05	0.000221	CcSEcCtD
Imatinib—Dyspepsia—Epirubicin—urinary bladder cancer	5.58e-05	0.000221	CcSEcCtD
Imatinib—Gastrointestinal pain—Methotrexate—urinary bladder cancer	5.54e-05	0.00022	CcSEcCtD
Imatinib—Decreased appetite—Epirubicin—urinary bladder cancer	5.51e-05	0.000219	CcSEcCtD
Imatinib—Hypotension—Doxorubicin—urinary bladder cancer	5.48e-05	0.000217	CcSEcCtD
Imatinib—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	5.47e-05	0.000217	CcSEcCtD
Imatinib—Fatigue—Epirubicin—urinary bladder cancer	5.47e-05	0.000217	CcSEcCtD
Imatinib—Constipation—Epirubicin—urinary bladder cancer	5.42e-05	0.000215	CcSEcCtD
Imatinib—Pain—Epirubicin—urinary bladder cancer	5.42e-05	0.000215	CcSEcCtD
Imatinib—Urticaria—Methotrexate—urinary bladder cancer	5.38e-05	0.000214	CcSEcCtD
Imatinib—Body temperature increased—Methotrexate—urinary bladder cancer	5.36e-05	0.000212	CcSEcCtD
Imatinib—Abdominal pain—Methotrexate—urinary bladder cancer	5.36e-05	0.000212	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	5.35e-05	0.000212	CcSEcCtD
Imatinib—Insomnia—Doxorubicin—urinary bladder cancer	5.31e-05	0.00021	CcSEcCtD
Imatinib—Paraesthesia—Doxorubicin—urinary bladder cancer	5.27e-05	0.000209	CcSEcCtD
Imatinib—Dyspnoea—Doxorubicin—urinary bladder cancer	5.23e-05	0.000207	CcSEcCtD
Imatinib—Feeling abnormal—Epirubicin—urinary bladder cancer	5.22e-05	0.000207	CcSEcCtD
Imatinib—Somnolence—Doxorubicin—urinary bladder cancer	5.22e-05	0.000207	CcSEcCtD
Imatinib—Gastrointestinal pain—Epirubicin—urinary bladder cancer	5.18e-05	0.000206	CcSEcCtD
Imatinib—Dyspepsia—Doxorubicin—urinary bladder cancer	5.16e-05	0.000205	CcSEcCtD
Imatinib—Decreased appetite—Doxorubicin—urinary bladder cancer	5.1e-05	0.000202	CcSEcCtD
Imatinib—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	5.06e-05	0.000201	CcSEcCtD
Imatinib—Fatigue—Doxorubicin—urinary bladder cancer	5.06e-05	0.000201	CcSEcCtD
Imatinib—Urticaria—Epirubicin—urinary bladder cancer	5.04e-05	0.0002	CcSEcCtD
Imatinib—Pain—Doxorubicin—urinary bladder cancer	5.02e-05	0.000199	CcSEcCtD
Imatinib—Constipation—Doxorubicin—urinary bladder cancer	5.02e-05	0.000199	CcSEcCtD
Imatinib—Body temperature increased—Epirubicin—urinary bladder cancer	5.01e-05	0.000199	CcSEcCtD
Imatinib—Abdominal pain—Epirubicin—urinary bladder cancer	5.01e-05	0.000199	CcSEcCtD
Imatinib—Hypersensitivity—Methotrexate—urinary bladder cancer	4.99e-05	0.000198	CcSEcCtD
Imatinib—Asthenia—Methotrexate—urinary bladder cancer	4.86e-05	0.000193	CcSEcCtD
Imatinib—Feeling abnormal—Doxorubicin—urinary bladder cancer	4.83e-05	0.000192	CcSEcCtD
Imatinib—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	4.8e-05	0.00019	CcSEcCtD
Imatinib—Pruritus—Methotrexate—urinary bladder cancer	4.79e-05	0.00019	CcSEcCtD
Imatinib—Hypersensitivity—Epirubicin—urinary bladder cancer	4.67e-05	0.000185	CcSEcCtD
Imatinib—Urticaria—Doxorubicin—urinary bladder cancer	4.66e-05	0.000185	CcSEcCtD
Imatinib—Abdominal pain—Doxorubicin—urinary bladder cancer	4.64e-05	0.000184	CcSEcCtD
Imatinib—Body temperature increased—Doxorubicin—urinary bladder cancer	4.64e-05	0.000184	CcSEcCtD
Imatinib—Diarrhoea—Methotrexate—urinary bladder cancer	4.64e-05	0.000184	CcSEcCtD
Imatinib—Asthenia—Epirubicin—urinary bladder cancer	4.55e-05	0.00018	CcSEcCtD
Imatinib—Pruritus—Epirubicin—urinary bladder cancer	4.49e-05	0.000178	CcSEcCtD
Imatinib—Dizziness—Methotrexate—urinary bladder cancer	4.48e-05	0.000178	CcSEcCtD
Imatinib—Diarrhoea—Epirubicin—urinary bladder cancer	4.34e-05	0.000172	CcSEcCtD
Imatinib—Hypersensitivity—Doxorubicin—urinary bladder cancer	4.32e-05	0.000171	CcSEcCtD
Imatinib—Vomiting—Methotrexate—urinary bladder cancer	4.31e-05	0.000171	CcSEcCtD
Imatinib—Rash—Methotrexate—urinary bladder cancer	4.27e-05	0.000169	CcSEcCtD
Imatinib—Dermatitis—Methotrexate—urinary bladder cancer	4.27e-05	0.000169	CcSEcCtD
Imatinib—Headache—Methotrexate—urinary bladder cancer	4.24e-05	0.000168	CcSEcCtD
Imatinib—Asthenia—Doxorubicin—urinary bladder cancer	4.21e-05	0.000167	CcSEcCtD
Imatinib—Dizziness—Epirubicin—urinary bladder cancer	4.19e-05	0.000166	CcSEcCtD
Imatinib—Pruritus—Doxorubicin—urinary bladder cancer	4.15e-05	0.000165	CcSEcCtD
Imatinib—Vomiting—Epirubicin—urinary bladder cancer	4.03e-05	0.00016	CcSEcCtD
Imatinib—Nausea—Methotrexate—urinary bladder cancer	4.02e-05	0.00016	CcSEcCtD
Imatinib—Diarrhoea—Doxorubicin—urinary bladder cancer	4.01e-05	0.000159	CcSEcCtD
Imatinib—Rash—Epirubicin—urinary bladder cancer	4e-05	0.000159	CcSEcCtD
Imatinib—Dermatitis—Epirubicin—urinary bladder cancer	3.99e-05	0.000158	CcSEcCtD
Imatinib—Headache—Epirubicin—urinary bladder cancer	3.97e-05	0.000158	CcSEcCtD
Imatinib—Dizziness—Doxorubicin—urinary bladder cancer	3.88e-05	0.000154	CcSEcCtD
Imatinib—Nausea—Epirubicin—urinary bladder cancer	3.77e-05	0.000149	CcSEcCtD
Imatinib—Vomiting—Doxorubicin—urinary bladder cancer	3.73e-05	0.000148	CcSEcCtD
Imatinib—Rash—Doxorubicin—urinary bladder cancer	3.7e-05	0.000147	CcSEcCtD
Imatinib—Dermatitis—Doxorubicin—urinary bladder cancer	3.7e-05	0.000147	CcSEcCtD
Imatinib—Headache—Doxorubicin—urinary bladder cancer	3.68e-05	0.000146	CcSEcCtD
Imatinib—Nausea—Doxorubicin—urinary bladder cancer	3.48e-05	0.000138	CcSEcCtD
Imatinib—CYP3A7—Metabolism—PPARG—urinary bladder cancer	6.44e-06	3.61e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PPARG—urinary bladder cancer	6.43e-06	3.6e-05	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—HRAS—urinary bladder cancer	6.4e-06	3.59e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—NQO1—urinary bladder cancer	6.39e-06	3.58e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—MYC—urinary bladder cancer	6.37e-06	3.57e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	6.35e-06	3.56e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—SRC—urinary bladder cancer	6.35e-06	3.56e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	6.33e-06	3.55e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ENO2—urinary bladder cancer	6.33e-06	3.55e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—FGFR3—urinary bladder cancer	6.33e-06	3.55e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IL2—urinary bladder cancer	6.32e-06	3.54e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—KRAS—urinary bladder cancer	6.32e-06	3.54e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—MYC—urinary bladder cancer	6.31e-06	3.54e-05	CbGpPWpGaD
Imatinib—LCK—Disease—PTGS2—urinary bladder cancer	6.3e-06	3.53e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	6.29e-06	3.53e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—SRC—urinary bladder cancer	6.29e-06	3.53e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CXCL8—urinary bladder cancer	6.25e-06	3.5e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PPARG—urinary bladder cancer	6.24e-06	3.5e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—CREBBP—urinary bladder cancer	6.24e-06	3.5e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—ERBB2—urinary bladder cancer	6.24e-06	3.5e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—EGFR—urinary bladder cancer	6.23e-06	3.5e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—GPX1—urinary bladder cancer	6.22e-06	3.49e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	6.18e-06	3.47e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—CREBBP—urinary bladder cancer	6.17e-06	3.46e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—EGFR—urinary bladder cancer	6.17e-06	3.46e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	6.17e-06	3.46e-05	CbGpPWpGaD
Imatinib—KIT—Disease—KRAS—urinary bladder cancer	6.16e-06	3.46e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—ESR1—urinary bladder cancer	6.14e-06	3.45e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	6.14e-06	3.44e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—NAT2—urinary bladder cancer	6.11e-06	3.43e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	6.1e-06	3.42e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—GSTP1—urinary bladder cancer	6.08e-06	3.41e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—RHOA—urinary bladder cancer	6.07e-06	3.4e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	6.05e-06	3.39e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—EGFR—urinary bladder cancer	6.02e-06	3.38e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—NQO1—urinary bladder cancer	6.02e-06	3.38e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—CREBBP—urinary bladder cancer	5.99e-06	3.36e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PPARG—urinary bladder cancer	5.99e-06	3.36e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IL2—urinary bladder cancer	5.97e-06	3.35e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—NQO1—urinary bladder cancer	5.97e-06	3.35e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—CDKN1A—urinary bladder cancer	5.96e-06	3.34e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—PTEN—urinary bladder cancer	5.95e-06	3.34e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CXCL8—urinary bladder cancer	5.91e-06	3.32e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—KRAS—urinary bladder cancer	5.89e-06	3.3e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.89e-06	3.3e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—EGFR—urinary bladder cancer	5.87e-06	3.29e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—KRAS—urinary bladder cancer	5.83e-06	3.27e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CCND1—urinary bladder cancer	5.82e-06	3.26e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	5.79e-06	3.25e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—CREBBP—urinary bladder cancer	5.75e-06	3.23e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	5.74e-06	3.22e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—KRAS—urinary bladder cancer	5.69e-06	3.19e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—MYC—urinary bladder cancer	5.69e-06	3.19e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—HRAS—urinary bladder cancer	5.67e-06	3.18e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—EP300—urinary bladder cancer	5.67e-06	3.18e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—TYMS—urinary bladder cancer	5.66e-06	3.17e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL2—urinary bladder cancer	5.65e-06	3.17e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MMP9—urinary bladder cancer	5.65e-06	3.17e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CDKN1A—urinary bladder cancer	5.63e-06	3.16e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—ERBB2—urinary bladder cancer	5.62e-06	3.15e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—PTEN—urinary bladder cancer	5.62e-06	3.15e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—GSTM1—urinary bladder cancer	5.59e-06	3.14e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—NCOR1—urinary bladder cancer	5.59e-06	3.14e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—EGFR—urinary bladder cancer	5.56e-06	3.12e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—KRAS—urinary bladder cancer	5.55e-06	3.11e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.54e-06	3.11e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—SRC—urinary bladder cancer	5.52e-06	3.09e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CCND1—urinary bladder cancer	5.51e-06	3.09e-05	CbGpPWpGaD
Imatinib—LCK—Disease—CDKN1A—urinary bladder cancer	5.5e-06	3.09e-05	CbGpPWpGaD
Imatinib—LCK—Disease—PTEN—urinary bladder cancer	5.49e-06	3.08e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	5.46e-06	3.06e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CREBBP—urinary bladder cancer	5.38e-06	3.02e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—HRAS—urinary bladder cancer	5.37e-06	3.01e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—EP300—urinary bladder cancer	5.36e-06	3.01e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—GPX1—urinary bladder cancer	5.35e-06	3e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MMP9—urinary bladder cancer	5.35e-06	3e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GSTP1—urinary bladder cancer	5.33e-06	2.99e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CDKN1A—urinary bladder cancer	5.33e-06	2.99e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CXCL8—urinary bladder cancer	5.33e-06	2.99e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—PTEN—urinary bladder cancer	5.32e-06	2.98e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IGF1—urinary bladder cancer	5.32e-06	2.98e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.28e-06	2.96e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—RRM2—urinary bladder cancer	5.28e-06	2.96e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—ERCC2—urinary bladder cancer	5.26e-06	2.95e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—KRAS—urinary bladder cancer	5.25e-06	2.95e-05	CbGpPWpGaD
Imatinib—KIT—Disease—HRAS—urinary bladder cancer	5.24e-06	2.94e-05	CbGpPWpGaD
Imatinib—LCK—Disease—EP300—urinary bladder cancer	5.24e-06	2.94e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TP53—urinary bladder cancer	5.23e-06	2.93e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—SRC—urinary bladder cancer	5.21e-06	2.92e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—KRAS—urinary bladder cancer	5.21e-06	2.92e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PTGS2—urinary bladder cancer	5.11e-06	2.86e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—NQO1—urinary bladder cancer	5.1e-06	2.86e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL2—urinary bladder cancer	5.09e-06	2.86e-05	CbGpPWpGaD
Imatinib—LCK—Disease—SRC—urinary bladder cancer	5.09e-06	2.86e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—TYMS—urinary bladder cancer	5.08e-06	2.85e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—EP300—urinary bladder cancer	5.07e-06	2.84e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	5.06e-06	2.84e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PTGS2—urinary bladder cancer	5.06e-06	2.84e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.05e-06	2.83e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	5.02e-06	2.82e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	5.02e-06	2.81e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	5.02e-06	2.81e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—HRAS—urinary bladder cancer	5e-06	2.81e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	4.98e-06	2.79e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CCND1—urinary bladder cancer	4.96e-06	2.78e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—HRAS—urinary bladder cancer	4.96e-06	2.78e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—TYMS—urinary bladder cancer	4.96e-06	2.78e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.95e-06	2.78e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—MTHFR—urinary bladder cancer	4.94e-06	2.77e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—SRC—urinary bladder cancer	4.93e-06	2.77e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PTGS2—urinary bladder cancer	4.91e-06	2.75e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—NCOR1—urinary bladder cancer	4.9e-06	2.75e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GSTM1—urinary bladder cancer	4.9e-06	2.75e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	4.89e-06	2.74e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ENO2—urinary bladder cancer	4.89e-06	2.74e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—RHOA—urinary bladder cancer	4.87e-06	2.73e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—HRAS—urinary bladder cancer	4.84e-06	2.71e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—EGFR—urinary bladder cancer	4.83e-06	2.71e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MMP9—urinary bladder cancer	4.82e-06	2.7e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.82e-06	2.7e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GPX1—urinary bladder cancer	4.81e-06	2.7e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CDKN1A—urinary bladder cancer	4.8e-06	2.69e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PTEN—urinary bladder cancer	4.79e-06	2.69e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	4.74e-06	2.66e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	4.72e-06	2.65e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—HRAS—urinary bladder cancer	4.71e-06	2.64e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PTGS2—urinary bladder cancer	4.71e-06	2.64e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GPX1—urinary bladder cancer	4.69e-06	2.63e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—TYMS—urinary bladder cancer	4.67e-06	2.62e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MYC—urinary bladder cancer	4.67e-06	2.62e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PPARG—urinary bladder cancer	4.65e-06	2.61e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—TYMS—urinary bladder cancer	4.63e-06	2.6e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TP53—urinary bladder cancer	4.63e-06	2.59e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	4.62e-06	2.59e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	4.62e-06	2.59e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—ERCC2—urinary bladder cancer	4.61e-06	2.58e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	4.58e-06	2.57e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	4.58e-06	2.57e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—EP300—urinary bladder cancer	4.57e-06	2.56e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—EGFR—urinary bladder cancer	4.57e-06	2.56e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—KRAS—urinary bladder cancer	4.57e-06	2.56e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MYC—urinary bladder cancer	4.56e-06	2.56e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—ERBB2—urinary bladder cancer	4.51e-06	2.53e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	4.47e-06	2.51e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—HRAS—urinary bladder cancer	4.47e-06	2.5e-05	CbGpPWpGaD
Imatinib—LCK—Disease—EGFR—urinary bladder cancer	4.46e-06	2.5e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PTEN—urinary bladder cancer	4.45e-06	2.5e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—SRC—urinary bladder cancer	4.44e-06	2.49e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	4.44e-06	2.49e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—HRAS—urinary bladder cancer	4.43e-06	2.48e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GPX1—urinary bladder cancer	4.42e-06	2.48e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MYC—urinary bladder cancer	4.42e-06	2.48e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PTEN—urinary bladder cancer	4.42e-06	2.48e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PTEN—urinary bladder cancer	4.41e-06	2.47e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GPX1—urinary bladder cancer	4.38e-06	2.46e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	4.34e-06	2.43e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—MTHFR—urinary bladder cancer	4.33e-06	2.43e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—EGFR—urinary bladder cancer	4.32e-06	2.42e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.32e-06	2.42e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—KRAS—urinary bladder cancer	4.31e-06	2.42e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	4.3e-06	2.41e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PTEN—urinary bladder cancer	4.28e-06	2.4e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CXCL8—urinary bladder cancer	4.28e-06	2.4e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	4.26e-06	2.39e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—EP300—urinary bladder cancer	4.25e-06	2.38e-05	CbGpPWpGaD
Imatinib—LCK—Disease—KRAS—urinary bladder cancer	4.22e-06	2.36e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—EP300—urinary bladder cancer	4.21e-06	2.36e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—EP300—urinary bladder cancer	4.2e-06	2.36e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.12e-06	2.31e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PTEN—urinary bladder cancer	4.11e-06	2.3e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL2—urinary bladder cancer	4.09e-06	2.29e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—KRAS—urinary bladder cancer	4.08e-06	2.29e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—EP300—urinary bladder cancer	4.08e-06	2.29e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	4.08e-06	2.29e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	4.04e-06	2.27e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PPARG—urinary bladder cancer	4.01e-06	2.25e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CCND1—urinary bladder cancer	3.98e-06	2.23e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MYC—urinary bladder cancer	3.98e-06	2.23e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—TYMS—urinary bladder cancer	3.96e-06	2.22e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—NQO1—urinary bladder cancer	3.94e-06	2.21e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—EP300—urinary bladder cancer	3.92e-06	2.2e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	3.91e-06	2.19e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	3.91e-06	2.19e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—EGFR—urinary bladder cancer	3.89e-06	2.18e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—HRAS—urinary bladder cancer	3.88e-06	2.18e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MMP9—urinary bladder cancer	3.87e-06	2.17e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CDKN1A—urinary bladder cancer	3.85e-06	2.16e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—CREBBP—urinary bladder cancer	3.85e-06	2.16e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PTEN—urinary bladder cancer	3.85e-06	2.16e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TP53—urinary bladder cancer	3.83e-06	2.15e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GPX1—urinary bladder cancer	3.75e-06	2.1e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—KRAS—urinary bladder cancer	3.68e-06	2.06e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	3.68e-06	2.06e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—HRAS—urinary bladder cancer	3.67e-06	2.06e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—EP300—urinary bladder cancer	3.67e-06	2.06e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	3.66e-06	2.05e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TP53—urinary bladder cancer	3.63e-06	2.04e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PPARG—urinary bladder cancer	3.6e-06	2.02e-05	CbGpPWpGaD
Imatinib—LCK—Disease—HRAS—urinary bladder cancer	3.58e-06	2.01e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—SRC—urinary bladder cancer	3.57e-06	2e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PPARG—urinary bladder cancer	3.51e-06	1.97e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—HRAS—urinary bladder cancer	3.47e-06	1.95e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	3.46e-06	1.94e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	3.46e-06	1.94e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CREBBP—urinary bladder cancer	3.37e-06	1.89e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PPARG—urinary bladder cancer	3.31e-06	1.86e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	3.28e-06	1.84e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PPARG—urinary bladder cancer	3.28e-06	1.84e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TP53—urinary bladder cancer	3.27e-06	1.83e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MYC—urinary bladder cancer	3.2e-06	1.79e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PTEN—urinary bladder cancer	3.19e-06	1.79e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	3.18e-06	1.78e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PTGS2—urinary bladder cancer	3.15e-06	1.77e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	3.15e-06	1.77e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—HRAS—urinary bladder cancer	3.13e-06	1.75e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—EGFR—urinary bladder cancer	3.13e-06	1.75e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—TYMS—urinary bladder cancer	3.05e-06	1.71e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—EP300—urinary bladder cancer	3.04e-06	1.71e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	3.02e-06	1.69e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	3.02e-06	1.69e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—KRAS—urinary bladder cancer	2.95e-06	1.66e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GPX1—urinary bladder cancer	2.89e-06	1.62e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	2.84e-06	1.59e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	2.83e-06	1.59e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PPARG—urinary bladder cancer	2.8e-06	1.57e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PTGS2—urinary bladder cancer	2.76e-06	1.55e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PTEN—urinary bladder cancer	2.75e-06	1.54e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	2.69e-06	1.51e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	2.67e-06	1.5e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TP53—urinary bladder cancer	2.62e-06	1.47e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—EP300—urinary bladder cancer	2.62e-06	1.47e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	2.6e-06	1.46e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	2.58e-06	1.45e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—HRAS—urinary bladder cancer	2.51e-06	1.41e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PTEN—urinary bladder cancer	2.47e-06	1.38e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PTEN—urinary bladder cancer	2.41e-06	1.35e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—EP300—urinary bladder cancer	2.35e-06	1.32e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—EP300—urinary bladder cancer	2.3e-06	1.29e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PTEN—urinary bladder cancer	2.27e-06	1.27e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PTEN—urinary bladder cancer	2.25e-06	1.26e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	2.2e-06	1.24e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—EP300—urinary bladder cancer	2.16e-06	1.21e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PPARG—urinary bladder cancer	2.16e-06	1.21e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—EP300—urinary bladder cancer	2.15e-06	1.2e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	2.08e-06	1.17e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PTEN—urinary bladder cancer	1.92e-06	1.08e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—EP300—urinary bladder cancer	1.83e-06	1.03e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.7e-06	9.54e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.48e-06	8.32e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.42e-06	7.94e-06	CbGpPWpGaD
